Acalabrutinib for mantle cell lymphoma

Thomas Elmer Witzig, David Inwards

Research output: Contribution to journalArticle

Abstract

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

Original languageEnglish (US)
Pages (from-to)2570-2574
Number of pages5
JournalBlood
Volume133
Issue number24
DOIs
StatePublished - Jan 1 2019

Fingerprint

Mantle-Cell Lymphoma
Cyclin D1
United States Food and Drug Administration
Non-Hodgkin's Lymphoma
Clinical Trials
Recurrence
acalabrutinib
Agammaglobulinaemia tyrosine kinase
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Acalabrutinib for mantle cell lymphoma. / Witzig, Thomas Elmer; Inwards, David.

In: Blood, Vol. 133, No. 24, 01.01.2019, p. 2570-2574.

Research output: Contribution to journalArticle

Witzig, Thomas Elmer ; Inwards, David. / Acalabrutinib for mantle cell lymphoma. In: Blood. 2019 ; Vol. 133, No. 24. pp. 2570-2574.
@article{b37e2f0411864eb7a6d5e00498208475,
title = "Acalabrutinib for mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81{\%}. It provides a valuable new treatment option for MCL patients and is now being tested upfront.",
author = "Witzig, {Thomas Elmer} and David Inwards",
year = "2019",
month = "1",
day = "1",
doi = "10.1182/blood.2019852368",
language = "English (US)",
volume = "133",
pages = "2570--2574",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Acalabrutinib for mantle cell lymphoma

AU - Witzig, Thomas Elmer

AU - Inwards, David

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

AB - Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma characterized by the overexpression of cyclin D1. MCL patients typically live for years but experience multiple relapses. Acalabrutinib is a novel second-generation oral Bruton tyrosine kinase inhibitor approved by the US Food and Drug Administration for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. It provides a valuable new treatment option for MCL patients and is now being tested upfront.

UR - http://www.scopus.com/inward/record.url?scp=85068040922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068040922&partnerID=8YFLogxK

U2 - 10.1182/blood.2019852368

DO - 10.1182/blood.2019852368

M3 - Article

VL - 133

SP - 2570

EP - 2574

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -